

Special Issue

Neurodevelopmental and Neuropsychiatric Disorders in Animal Models

Message from the Guest Editor

Neurodevelopmental and neuropsychiatric disorders are complex conditions that can have a myriad of clinical manifestations and are influenced by multiple biological, environmental and genetic factors. Considering that access to human data may be hampered by ethical concerns, technical and analytical limitations, the use of animal models stands out as an alternative of translational significance. This Special Issue intends to gather information aiming to help fill knowledge gaps and provide valuable insights into the complex nature of neurodevelopmental and neuropsychiatric disorders. Accordingly, the scope of the issue covers a broad range of topics from the understanding of their molecular bases to the development of new therapeutic strategies. Preclinical research articles, reviews, and perspectives that cover these and related topics are welcome.

- mood disorder
- mental disorder
- substance use disorder
- autism spectrum disorder (ASD)
- attention-deficit/hyperactive disorder (ADHD)
- depression and anxiety disorders
- schizophrenia
- bipolar disorder
- epilepsy
- eating disorders

Guest Editor

Prof. Dr. Yael Abreu-Villaça

Laboratório de Neurofisiologia, Departamento de Ciências Fisiológicas, Instituto de Biologia Roberto Alcântara Gomes, Universidade do Estado do Rio de Janeiro (UERJ), Rio de Janeiro 20550-170, RJ, Brazil

Deadline for manuscript submissions

30 November 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/224740

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).